Interim results from Protective-2 RCT in US demonstrates superiority of plinabulin in combination with pegfilgrastim for chemotherapy-induced neutropenia prevention

Interim analysis (n=120) reports plinabulin, a guanine nucleotide exchange factor stimulant, plus pegfilgrastim reduced the rate of severe (Grade 4) neutropenia in first chemotherapy cycle vs pegfilgrastim alone (p<0.01).

SPS commentary:

UK and EU developmental status of plinabulin is currently unknown. Pegfilgrastim is already licensed in the UK to reduce the duration and incidence of neutropenia and febrile neutropenia.


Biospace Inc.